Skip to Content
Merck
All Photos(2)

Key Documents

SML3959

Sigma-Aldrich

VS-5584

≥98% (HPLC)

Synonym(s):

5-(9-Isopropyl-8-methyl-2-morpholin-4-yl-9H-purin-6-yl)-pyrimidin-2-ylamine, 5-[8-Methyl-9-(1-methylethyl)-2-(4-morpholinyl)-9H-purin-6-yl]-2-pyrimidinamine, SB 2343, SB-2343, SB2343, VS 5584, VS5584

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C17H22N8O
CAS Number:
Molecular Weight:
354.41
MDL number:
UNSPSC Code:
12352200
NACRES:
NA.77

Quality Level

Assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

-10 to -25°C

Biochem/physiol Actions

Orally active, potent and highly selective mTOR and class I phosphoinositide 3-kinases (PI 3-kinases; PI3K) inhibitor with anti-cancer efficacy in vitro and in vivo.


VS-5584 (SB2343) is an orally active, potent and highly selective mTOR (IC50 = 37 nM) and class I phosphoinositide 3-kinases (PI 3-kinases; PI3K IC50 = 16 nM/α, 68 nM/β, 25 nM/γ, 42 nM/δ; little activity toward 400 other lipid and protein kinases) inhibitor with broad-spectrum anti-proliferation activity in cancer cultures (IC50 post 48h treatment from 48 nM to 1.75 μM among 50 cancer lines) by inhibiting PI3K and mTOR downstream substrates phosphorylation. VS-5584 displays tumor growth inhibition efficacy in various rapalog-sensitive and -resistant human xenograft models in mice in vivo (PC3 TGI = 79% and 113%, respectively, post 28-day 11 mg/kg or 25 mg/kg daily p.o. treatment).

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Structure and ligand-based design of mTOR and PI3-kinase inhibitors leading to the clinical candidates VS-5584 (SB2343) and SB2602
Journal of Chemical Information and Modeling, 54(11), 3238-3250 (2014)
PI3K/mTOR dual inhibitor VS-5584 preferentially targets cancer stem cells
Cancer Research, 75(2), 446-455 (2015)
Stefan Hart et al.
Molecular cancer therapeutics, 12(2), 151-161 (2012-12-29)
Dysregulation of the PI3K/mTOR pathway, either through amplifications, deletions, or as a direct result of mutations, has been closely linked to the development and progression of a wide range of cancers. Moreover, this pathway activation is a poor prognostic marker

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service